Efforts to develop vaccines that can elicit mucosal immune responses in the female genital tract against sexually transmitted infections have been hampered by an inability to measure immune responses in these tissues. The differential expression of adhesion molecules is known to confer site-dependent homing of circulating effector T cells to mucosal tissues. Specific homing molecules have been defined that can be measured in blood as surrogate markers of local immunity (e.g. α4β7 for gut). Here we analyzed the expression pattern of adhesion molecules by circulating effector T cells following mucosal infection of the female genital tract in mice and during a symptomatic episode of vaginosis in women. While CCR2, CCR5, CXCR6 and CD11c were preferentially expressed in a mouse model of Chlamydia infection, only CCR5 and CD11c were clearly expressed by effector T cells during bacterial vaginosis in women. Other homing molecules previously suggested as required for homing to the genital mucosa such as α4β1 and α4β7 were also differentially expressed in these patients. However, CD11c expression, an integrin chain rarely analyzed in the context of T cell immunity, was the most consistently elevated in all activated effector CD8 + T cell subsets analyzed. This molecule was also induced after systemic infection in mice, suggesting that CD11c is not exclusive of genital tract infection. Still, its increase in response to genital tract disorders may represent a novel surrogate marker of mucosal immunity in women, and warrants further exploration for diagnostic and therapeutic purposes.
Introduction
Female genital tract (FGT) infections, including common sexually transmitted infections (STI), seriously compromise the health of women. Worldwide, more than 340 million new cases of treatable STI occur each year and they are estimated to be the leading cause of morbidity in women in developing countries [1] . Furthermore, pre-existing FGT infections affect the development and pathogenesis of other STI, as occurs with the pro-inflammatory environment generated by bacterial vaginosis (BV) and the enhancement of human immunodeficiency virus (HIV) replication [2] . The long-term consequences of STI, including pelvic inflammatory disease, cancer, infertility, stillbirth, etc. not only are highly relevant at the social and health level, but also have a major economic impact.
Although effective vaccines exist for human papilloma virus and hepatitis B virus, efforts to develop vaccines against herpes simplex virus type 2 (HSV-2), HIV and bacterial STI have been hampered by an inability to effectively measure immune responses in the genital tract. Such vaccines need to be able to generate robust immune responses at site of potential exposure in order to provide rapid control of primary infection [3, 4] . Mucosal T cells and, notably, cytotoxic T lymphocytes play a critical role in the clearance of sexually transmitted pathogens [4] . For instance, studies in human have confirmed the association of T cell-mediated immunity with clearance of Chlamydia infection [5] and susceptibility to re-infection [6] . Moreover, the presence of antiviral effector CD8 + T cells in the vagina of immunized monkeys correlates with protection from uncontrolled viremia after pathogenic challenge with simian immunodeficiency virus [7] . In these models of genital infection, the induction of effector memory T (T EM ) cells and antibodies that are able to mount fast responses upon re-challenge is critical to control the pathogen. However, current assays used to understand the magnitude and quality of immune responses in the FGT rely primarily on blood samples and thus provide an incomplete picture of localized immune control. The capacity of distinct subsets of antigen-experienced lymphocytes to traffic preferentially into specific compartments is termed homing. T EM cell entry into inflamed non-lymphoid tissues is an active process involving members of the integrin, selectin-ligand and chemokinereceptor families, which mediate selective interactions of circulating lymphocytes with the specialized vascular endothelium [8] . While some adhesion molecules are enriched for a given tissue, e.g. α4β7 integrin and CC chemokine receptor CCR9 are associated with homing of T cells to the gut and cutaneous lymphocyte-associated antigen (CLA) and CCR4/CCR10 with T cell homing to the skin, other molecules are specialized for tissue-inflammatory functions to multiple tissues, such as CXCR3 or αLβ2 [9, 10] . Importantly, many properties that enable T cells to traffic to specific locations are programmed during the early stages of the infection [11] . Analysis of blood samples during the primary immune response to yellow fever immunization in humans suggests that human virus-specific CD8 + T cells express a dynamic pattern of homing molecules early after immune activation [12] . Thus, analysis of lymphocytes in blood will not reflect the quantity/quality of non-recirculating resident memory T cells [11] , and sampling directly from mucosal surfaces will be required to define correlates of protection after vaccination. However, after activation, there is a window of opportunity to examine circulating lymphocytes in blood as they are homing to a specific mucosal tissue. In contrast to the gastrointestinal tract or the skin, our understanding of homing receptors that are required for cells migrating to the FGT is limited. α4β7 was proposed to recruit CD4 + T cells to the vaginal mucosa of mice infected with Chlamydia [13] . Yet, a recent paper demonstrated that this integrin is not necessary for CD4 + T cell-mediated protection against Chlamydia trachomatis infection, while α4β1 appears to drive homing of protective cells into the murine upper genital tract [14] . Other papers using animal models support these findings [15] and expression of vascular cell adhesion molecule-1, which binds this integrin, has been detected in the human vagina [16, 17] . Nonetheless, another recent paper demonstrated that circulating CD4 + T cells from asymptomatic HSV-2-infected patients express higher levels of α4β7 than uninfected patients [18] . Lastly, other investigators have described homing receptors that are shared between immune cells migrating to the skin and the FGT [16, 19] . Here, we hypothesized that defining the homing profiles of lymphocytes migrating towards the genital tract could potentially be used as a surrogate marker of FGT immunity. We found that T EM cells from mice intravaginally-infected with Chlamydia muridarum expressed high levels of CCR2, CCR5, CXCR6 and CD11c. When comparing these homing profiles to women with different mucosal or skin disorders, unique features were detected in each of the cohorts, compared to healthy patients. Of particular interest, CD11c was strikingly increased in CD8 + T EM cells from patients with BV and thus could serve as a novel indirect marker of FGT immunity.
Materials and Methods

Ethics statement
All mice were maintained in accordance with the recommendations of the Association for Assessment and Accreditation of Laboratory Animal Care International Standards and with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The Institutional Animal Use and Care Committee of the University of California, Davis, approved these experiments (Protocol # 18299). Informed written consent was obtained from all participants and the study protocol and questionnaire was approved by the University Hospital Germans Trias i Pujol (HUGTP, Badalona, Spain) Clinical Research Ethics Committee (reference # EO-11-074). The study was undertaken in accordance with the Declaration of Helsinki and the requirements of Good Clinical Practice.
Animal model
Chlamydia muridarum strain Weiss was purchased from ATCC (Manassas, VA) and propagated in HeLa 229 cells in Dulbecco's modified Eagle's medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS). C. muridarum elementary bodies (EBs) were purified by discontinuous density gradient centrifugation as previously described and stored at -80°C [20] . The number of inclusion-forming units of purified EBs was determined by infection of HeLa 229 cells and enumeration of inclusions that were stained with anti-Chlamydia major outer membrane protein antibody (a kind gift from Dr. Harlan Caldwell). Eight weeks old C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). For systemic infection, mice were intravenously (IV) injected in the lateral tail vein with 1x10 5 C. muridarum. For vaginal infection, estrus was synchronized by subcutaneous injection of 2.5 mg medroxyprogesterone acetate (Greenstone, NJ). Seven days after, 1x10 5 C. muridarum in 5μL sucrose/phosphate/glutamate buffer were deposited directly into the vaginal vaults with a blunted pipet tip [21] . Seven, 10 and 14 days post-infection, blood was collected by retro-orbital bleeding. Immediately after collection, blood samples for cell sorting and validation analyses were air-shipped from the laboratory of Dr. McSorley (CCM, UC Davis, CA) to the laboratory of Dr. Genescà (IGTP, Badalona, Spain). Samples arrived refrigerated and in good conditions 48 hours later and were immediately processed.
Cell sorting
Circulating T EM cells were sorted from six 7 days Chlamydia-infected mice (VAG group) and six contemporary sham-treated mice (control group). Blood samples (~500μl) were immediately lysed using an in-house red blood cell lysis buffer. ples were mixed for a minute and after a short spin, the volume of RLT was adjusted (3.5:1 ratio of RLT to sheath fluid) using filtered tips. Samples were mixed and spun again and immediately frozen at -80°C.
Gene expression analyses
Total RNA was isolated from cells using RNA easy Mini kit (QIAGEN). After qualitative assessment of RNA integrity, samples were amplified using Whole Transcriptome Amplification 2 (Sigma-Aldrich, Madrid, Spain). We chose four samples in each group that qualified for microarray analyses, yet one sample from the VAG and control group were discarded after as outliers, thus microarray analyses were performed in n = 3 for the VAG group and n = 3 for the control group (which were actually contemporary samples). The number of sorted cells in each group was similar (15,207 ± 2,339 cells for the VAG group and 20,793 ± 2,443 cells for the control group; not significant). Affymetrix microarray hybridization was performed using the Mouse Genome 430 PM Strip platform. Images intensities were extracted using GeneAtlas System software (Affymetrix), normalized and summarized using Robust Multi-array Average algorithm. Differential gene expression analysis was assessed by fitting to an empirical Bayesian linear model. Statistical significance in differential gene expression was computed with a false discovery rate multiple testing adjustment correction. For this analysis we used the Limma package and the R statistical programming environment [22] . The 'compute overlaps' function in the 'investigate gene sets web application (http://www.broadinstitute.org/gsea/msigdb/annotate.jsp) of the Molecular Signatures Database v4.0 (MaSigDB) was used to explore functions enriched among the top regulated genes defined as having a nominal (non-adjusted) p-value <0.005. The lists of gene symbols up-regulated and down-regulated in infected versus uninfected samples were scrutinized for significant overlaps with pathway (C2: CP, KEGG) and immunologic signatures (C7) in MaSigDB [23] .
Flow cytometry validation analyses in mice
Blood samples (~500μl) were immediately lysed, washed, suspended in PBS and incubated with Aqua vital dye to distinguish live from dead cells (Invitrogen, Burlington, ON, Canada). Following two more washes, cells were suspended in washing and staining buffer (1% bovine serum albumin-PBS) and incubated for 20 minutes with the following cocktail of pre-titrated anti-mouse antibodies: CD3-Vioblue (145-2C11), CD4-APC-H7 (GK1.5), CD62L-PE (MEL-14-H2.100) (Miltenyi Biotec), CD44-Brilliant Violet 570 (IM7; BioLegend, San Diego, CA), CD11c-PE-Cy7 (HL3; BD Biosciences) and CCR5-FITC (CTC5), CXCR6-PerCP (221002) and CCR2-APC (475301) (R&D Systems Inc., Minneapolis, MN). All events were acquired in a BD FACSAria™ Cell Sorter and analyzed with FlowJo vX.0.7 software (TreeStar, Ashland, OR).
Participant enrolment and inclusion criteria for human samples
All participants for this study Participants completed a questionnaire in order to detect possible exclusion criteria (other chronic or acute diseases, allergies or infections, immunosuppressive treatment, etc.) and register menstrual cycle and birth control data. Patients included in each cohort presented either an active burst (for PS and UC groups) or symptoms compatible with a recent infection within the last 7 days (for BV group). Inclusion criteria for the PS group consisted on women with acute psoriasis vulgaris that suffered a relapse of less than two weeks, with no treatment for at least six weeks. UC subjects were women with active ulcerative colitis: the extent of pathology was defined based on the Montreal classification [24] and the severity of disease on the Mayo's Disease Activity Index [25] . Only patients with active burst (index >9) off immunosuppressive treatment were included. Lastly, not-treated and symptomatic BV infections defined by Nugent scoring of >7 and suspected of Gardnerella vaginalis origin were confirmed by microscopic examination (more than 20% of clue cells). Patients with other STI were excluded.
Human T cell phenotype
Blood was collected and processed within 4 hours maximum. An ammonium chloride-based lysing reagent (BD Pharm Lyse, BD Biosciences) was used for erythrocyte deletion of 1ml of blood. After washing, cells were suspended in PBS and stained with Aqua Dye (Invitrogen) for cell viability. Cells were washed again, suspended in staining buffer and divided in four tubes. The four different panels assessed contained some common and some specific antibodies. Common antibodies were: CD3-eFluor 605, CD4-Alexa700 (eBioscience, San Diego, CA), CCR7-Horizon PE-CF594, CD38-Brillant Violet 421, HLA-DR-PerCP-Cy5.5 and CD11c-PE-Cy7 (BD Biosciences). Specific for each panel were: 1) CCR2-PE, CCR5-APC-Cy7, CXCR6-APC (R&D Systems Inc.) and CXCR3-FITC (BioLegend); 2) CD49d (α4)-FITC, β7-APC, CCR9-PE (BD Biosciences) and CD29 (β1)-APC-Cy7 (BioLegend); 3) CD103-FITC, CD54-APC, CD49a (α1)-PE and CD29-APC-Cy7 (BioLegend); 4) CD18-APC, CLA-FITC (BD Biosciences) and CCR10-PE (BioLegend). Cells were acquired using a BD LSRFortessa SORP flow cytometer (Flow Cytometry Platform, IGTP) and analyzed with FlowJo 9.3.2 software (TreeStar). Gates were drawn based on fluorescence minus one-controls and isotypes, and CD3 + CD4 -phenotype was considered CD8 + T cells.
Tissue processing and flow cytometry
Mouse spleen and iliac lymph nodes were harvested and a single-cell suspension prepared. Peripheral blood was collected by retro-orbital bleeding. Red blood cells were removed by ACK lysing buffer (Life Technologies). Leukocytes were washed with FACS buffer (PBS with 2% FBS) and stored on ice until use. Mouse genital tract were removed and leukocytes isolated as described [26] . Briefly, mouse genital tract (vagina, cervix, uterine horns, oviducts) were minced into small pieces, digested in 500mg/L collagenase IV (Sigma) for 1 hour at 37°C with constant stirring. Leukocytes were purified by percoll density gradient centrifugation (GE Healthcare), washed with FACS buffer and stored on ice until use. Single cell suspensions from spleen, dLNs, blood and genital tract were prepared in FACS buffer and blocked with Fc block (culture supernatant from the 24G2 hybridoma, 2% mouse serum, 2%, rat serum, and 0.01% sodium azide). Cells were then stained with anti-CD11b, F4/80 and B220-FITC together with MHCII PerCP-Cy5.5 (as dump channels), CD4-APCeFluor780, CD8-Pacific Orange, CD44-Alexa 700 and CD11c-APC. All flow antibodies were obtained from eBiosciences. Samples were acquired on an LSRFortessa flow cytometer and analyzed using FlowJo software (TreeStar).
Statistical Analysis
Data are reported as the median and IQR for each animal group or cohort using Prism 4.0 software (GraphPad Software). Statistical analyses were performed by non-parametric Mann Whitney test to compare single time points between two groups (case vs. control) using SPSS software for Windows version 13.0 (Chicago, IL). P value of <0.05 was considered significant.
Accession codes
Microarray data presented in this article are deposited into the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE67147.
Results
Differentially expressed genes after genital tract infection in mice
To address the homing profile of T EM cells shortly after vaginal infection, blood CD3 + CD62L -CD44 + T cells were sorted from Chlamydia-infected mice (VAG group) and sham-treated mice (control group) 7 days post-infection in a pilot experiment. After qualitative assessment of the sample RNA integrity and amplification, we chose three samples in each group that qualified for microarray analyses. We detected highly significant differences in genes involved in interferon signaling, synthesis of DNA, cell cycle and activation of the immune system between the two groups ( Table 1) . Regarding adhesion molecules, several chemokine receptors and integrin genes were significantly up-regulated in infected animals compared to the control group and the four most significant genes were selected for further validation: Ccr5, Itgax, Cxcr6 and Ccr2 (Fig 1) .
Higher frequency of circulating CD11c + CD8 + T cells is detected early after Chlamydia infection
In order to confirm the expression of these molecules, we analyzed a 10-color panel by flow cytometry at 7, 10 and 14 days post-infection. In general, the percentage of CCR2, CCR5, CXCR6 and CD11c (Itgax) in live CD4 + or CD4 -(putative CD8 + ) T cells peaked 10 days after infection, when in most cases their total frequency was significantly higher than in the control group (S1 Fig and/or 14 days post-infection than in the control group (Fig 2a, 2g, 2e and 2c ). In contrast, we detected a higher percentage of CXCR6 seven days after infection and of CD11c at all-time points in the CD8 + CD44 + T EM cells compared to the control group (Fig 2e and 2g) . Although expression of these markers was also increased in the non-activated fraction of both T EM cell subsets, the magnitude of expression was much lower (Fig 2b, 2d, 2f and 2h) . Thus, all the selected up-regulated genes were confirmed by protein expression. While CCR2 and CCR5
were only increased in the CD4 + T EM cell subset after infection, expression of CXCR6 and CD11c was much more abundant in CD8 + T EM cells.
CD11c expression increases in human circulating CD8 + T EM during symptomatic vaginosis
We next addressed the expression of these and other potentially relevant mucosal homing molecules in peripheral blood T EM cells from healthy young women (ND) in comparison to women with psoriasis (PS), ulcerative colitis (UC) and BV. First, we analyzed the expression of the different molecules by CD4 + and CD4 -(putative CD8 + ) T cells in CCR7 -T EM cells from thirteen ND, as shown in the general gating strategy (Fig 3 and S2 Fig) . All these molecules were also analyzed based on the activation markers included (CD38/HLA-DR) in order to detect associations between them. We observed a higher percentage of circulating CCR7 -CD4 + T cells expressing the CCR2, CCR9 and CCR10 chemokine receptors compared to CD8 + T cells, while there was a higher percentage of circulating CD8 + T EM cells expressing CCR5 and CXCR6 compared to CD4 + T EM cells (Fig 4) . Regarding integrins and other molecules, the frequency of α1β1, α4β7 and CLA was in general higher in CD4 + T EM cells than in CD8 + , while the frequency of α4β1 and CD11c was higher in CD8 + T EM cells (Fig 4) . Finally, the frequency of CXCR3 did not show any differences between these subsets, while CD103 was only higher in the HLA-DR + fraction of circulating CCR7 -CD4 + T cells compared to CD8 + T cells (S4 Fig). Next we compared the expression of these adhesion molecules in ND with their expression in different mucosal and skin disorders. Of note, there was an overall decrease of the percentage of CD4 + T cells in the different groups of patients that was only significant for the BV cohort ( S5 Fig). When analyzing the T EM cell fractions, we detected a significant increase in at least one of the activation markers in each cohort, which denoted the pathological condition of the patients (Fig 5) . Since activated T EM cells more likely contain specific T cells migrating towards the inflamed tissues [27] , we focused on the differences detected in the double activated fraction (Fig 6) . This way, the only significant changes within CD38 + HLA-DR + T EM cells from the PS group compared to ND were: increased frequency of CCR9 in CD8 T EM cells, increased frequency of α1β1 in CD4 + T EM cells, and a significant decrease of α4β1 and α4β7 in CD8 + T EM cells (Fig 6) . In fact, the decrease of α4β7 in CD8 + T EM cells was a general observation in all groups of patients (Fig 6d) , which was predominantly significant in the CD38 + fraction (S7 Fig). UC group characteristic profile in CD38 + HLA-DR + T EM cells was an increase of α1β1 percentage in CD4 + T EM cells (as occurred in the PS group) (Fig 6c) . Lastly, the BV group shared the decrease in the percentage of α4β7 expression in CD8 + T EM cells with the PS group. As for the unique features in BV patients, we detected higher frequency of CCR5 and α4β1 in CD4 + T EM cells with a concomitant decrease in the frequency of α4β7 in these cells, and also exclusive high percentage of CD11c in CD8 + T EM cells (Fig 6) . In summary, increased expression of CCR5 and CD11c on CD4 + and CD8 + T EM cells respectively was confirmed in women with symptomatic BV.
CD11c expression in blood after vaginal infection correlates with an increase in the genital tract but is not exclusive of infection in these tissues
Considering that CD11c was the most striking and novel marker of genital tract condition in both, mice and women, we performed additional experiments to address if this increase was exclusive of productive infection in these tissues or, in contrast, was a consequence of bacterial infection in general. Therefore, we performed a new set of animal experiments in which we included an intravenously (IV) Chlamydia-infected group. It is important to note that IV infection induces bacterial replication in different systemic and also mucosal tissues, including spleen and lung [21] . Interestingly, seven days post-infection the frequency of CD11c (Fig 7) . In the control and the VAG groups we obtained cell suspensions from the genital tract to determine the frequency of CD11c + T cells. As shown (Fig 7) , seven days after infection, the total frequency of CD3 + CD11c + in genital tract increased from a median of [46] [47] [48] [49] [50] [51] [52] [53] in the genital tract. Thus, 7 and 14 days after infection, CD11c expression increases in the genital tract of mice correlating with the increase observed in blood. However, CD11c increased expression is not specific to infection in the genital tract, since systemic infection also expands this subset.
Discussion
We interrogated the expression of multiple adhesion molecules in circulating T EM cells from different groups of women with disorders affecting primarily peripheral tissues. We report for the first time that women with BV have higher frequency of CD8 + T EM expressing CD11c. This increase was not observed during inflammatory pathologies affecting the gastrointestinal tract or the skin. Importantly, we also detected an increase in CD11c gene and protein expression in a mouse model of Chlamydia reproductive tract infection in both, blood and genital tract. Other patterns of integrin and chemokine receptor expression were also observed in patients with BV. In particular, the expression of CCR5 and α4β1 was increased in circulating CD4 + T EM cells of these women compared to healthy donors.
The increased expression of CD11c in T EM cell subsets soon after vaginal infection or during an episode of vaginosis was a strong and consistent finding in mice and women. Although the expression of CD11c has been classically used to identify dendritic cells, this α-chain integrin is also expressed in other myeloid cells, NK cells and populations of activated T and B cells [28] . Specifically within the activated T cell fraction, CD11c expression has been associated to effector and regulatory T cells in different mouse models [29] [30] [31] [32] [33] , as well as with intraephitelial lymphocytes in the small gut [34, 35] . More recently, some authors have described the existence of a unique subset in mice and importantly, in humans, that combine key features of T and dendritic cells [36] . These cells are positive for T cell receptor, major histocompatibility complex II and CD11c + and, regardless of their lymphocyte morphology, posses antigen presenting cell and innate-like properties [36] . However, to our knowledge, no specific report on expression of CD11c in human T cells in association to a mucosal condition has ever been published. A considerable constraint in our study is the comparison between the cohorts evaluated. Although all these disorders have a clear Th1 component [37] [38] [39] , they have very different origins and associated inflammation, and no other mucosal disorder with a bacterial component could be compared to the BV group. This fact, the Chlamydia systemic infection experiment results (Fig 7) and supporting animal models that demonstrate CD11c expression in T cells after systemic vaccination and infection [29] [30] [31] [32] [33] , indicates that CD11c expression is not specific to genital tract infection, rather indicative of activation and recirculation in general. Moreover, there was a trend towards higher percentage of CD11c + in T cells from patients with UC that was significant in the HLA-DR fraction (S8 Fig). Although we acknowledge the limitation of the sample size for the cohorts included in the study, the present results represent a unique comparison between peripheral tissue alterations that provide adhesion molecules of interest for each of the different disorders to further explore. In any case, this is the first report demonstrating enhanced CD11c expression in CD8 + T EM cells after intravaginal Chlamydia infection in mice and symptomatic BV in women, and we are currently working on defining the phenotype and role of these cells in these models. The differential expression of certain adhesion molecules can induce a site-dependent homing profile that may work together with some other generic signals (such as CXCR3, CCR3, CCR5 and CCR6) [10] . Previous studies have examined adhesion molecules necessary for homing to the upper genital tract in a mouse model of C. trachomatis infection by directly infecting the uterine horns [14, 40] . In this model, CXCR3, CCR5 and α4β1 are required for homing of protective T cells to the murine upper genital tract [14, 40] . Interestingly, samples from women with symptomatic BV, confirmed two of these molecules as potentially involved in FGT homing in humans. The frequency of integrin α4β1 was indeed up regulated in CD4 + T EM cells, which correlates with high expression of this integrin in the genital mucosa of women [41] . Moreover, BV patients did also showed a higher percentage of CCR5 expression in their CD4
+ T EM cells compared to ND, indicating that CCR5 might indeed be necessary for FGT homing as suggested [40] . Asymptomatic genital HSV-2 infection is also associated with increased expression of CCR5 by endocervical CD4 + T cells and similar trends were observed in circulating CD4 + T cells [18] . Further, a live-attenuated vaccine that continuously replicates in systemic and mucosal tissues in macaques also induces increased frequency of peripheral CD4 + T cells expressing CCR5, and the two animals with the highest percentage of this population had the highest number of specific T cells in the genital tract [42] . However, a recent report on the effect of vaginal immunization in women showed a clear down-regulation of CCR5 on CD4 + T cells after immunization [43] . Nevertheless, the first time-point analyzed in that study was 4 weeks post-immunization, when major recirculation and infiltration of T cells may have already occurred [12] . Of great importance is the fact that this increment is detected in the CD4 + T EM cell population, since CCR5 is a co-receptor for HIV and thus could have highly detrimental effects favoring HIV infection susceptibility [44, 45] . If higher numbers of CCR5 expressing CD4 + T EM cells are indeed infiltrated in the genital tissue during BV episodes, this could partially explain its association with higher risk of HIV-1 acquisition [46] . cells in the periphery decreases inversely to disease severity during acute psoriasis [47] . Further, CLA interacts with E-selectin expressed on venular endothelial cells not only from inflamed skin, but also from oral mucosa and FGT, and genital HSV-specific CD8 + T cells in the peripheral blood express high levels of CLA [16, 19] . Yet α4β7, another molecule described in asymptomatic HSV-2-infected patients but not in uninfected patients [18] , was down regulated in activated T EM cells from BV patients (Fig 6) . While this decrease could also indicate selective infiltration of these cells into the infected tissues early after infection, the existence of a mechanism that would actually down-regulate some of these molecules cannot be discarded. Many properties that enable T cells to traffic to specific locations are programmed during the early stages of the infection [11] . Thus, in order to understand the homing patterns and dynamics of the mucosal response associated to vaccination and infection, we need to analyze specific and activated T cells responses early after activation [4, 12] . In summary, in this study we define adhesion molecules, namely CCR5, α4β1 and CD11c, which may be desirable to induce in order to generate an effective mucosal response in vaccine candidates against STI. Special attention should be given to CD11c as a novel marker of T cell mucosal immunity in response to genital tract disorders.
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